Aclaris Therapeutics (ACRS) Competitors $1.81 -0.03 (-1.63%) Closing price 04:00 PM EasternExtended Trading$1.80 -0.01 (-0.55%) As of 05:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACRS vs. AMLX, IOVA, PHAT, URGN, TRVI, DNTH, AVBP, AVXL, ABUS, and KALVShould you be buying Aclaris Therapeutics stock or one of its competitors? The main competitors of Aclaris Therapeutics include Amylyx Pharmaceuticals (AMLX), Iovance Biotherapeutics (IOVA), Phathom Pharmaceuticals (PHAT), Urogen Pharma (URGN), Trevi Therapeutics (TRVI), Dianthus Therapeutics (DNTH), ArriVent BioPharma (AVBP), Anavex Life Sciences (AVXL), Arbutus Biopharma (ABUS), and KalVista Pharmaceuticals (KALV). These companies are all part of the "pharmaceutical products" industry. Aclaris Therapeutics vs. Its Competitors Amylyx Pharmaceuticals Iovance Biotherapeutics Phathom Pharmaceuticals Urogen Pharma Trevi Therapeutics Dianthus Therapeutics ArriVent BioPharma Anavex Life Sciences Arbutus Biopharma KalVista Pharmaceuticals Aclaris Therapeutics (NASDAQ:ACRS) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability. Do analysts recommend ACRS or AMLX? Aclaris Therapeutics presently has a consensus price target of $8.71, suggesting a potential upside of 381.45%. Amylyx Pharmaceuticals has a consensus price target of $14.50, suggesting a potential upside of 13.55%. Given Aclaris Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Aclaris Therapeutics is more favorable than Amylyx Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aclaris Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11Amylyx Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 3.00 Which has more volatility and risk, ACRS or AMLX? Aclaris Therapeutics has a beta of 0.27, indicating that its share price is 73% less volatile than the S&P 500. Comparatively, Amylyx Pharmaceuticals has a beta of -0.44, indicating that its share price is 144% less volatile than the S&P 500. Is ACRS or AMLX more profitable? Amylyx Pharmaceuticals has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -802.03%. Aclaris Therapeutics' return on equity of -34.01% beat Amylyx Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Aclaris Therapeutics-802.03% -34.01% -24.18% Amylyx Pharmaceuticals N/A -82.48%-70.15% Which has preferable earnings and valuation, ACRS or AMLX? Aclaris Therapeutics has higher earnings, but lower revenue than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Aclaris Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAclaris Therapeutics$18.72M10.47-$132.07M-$1.37-1.32Amylyx Pharmaceuticals$87.37M13.03-$301.74M-$2.50-5.11 Do insiders and institutionals have more ownership in ACRS or AMLX? 98.3% of Aclaris Therapeutics shares are owned by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. 5.6% of Aclaris Therapeutics shares are owned by insiders. Comparatively, 12.3% of Amylyx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media favor ACRS or AMLX? In the previous week, Amylyx Pharmaceuticals had 9 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 11 mentions for Amylyx Pharmaceuticals and 2 mentions for Aclaris Therapeutics. Aclaris Therapeutics' average media sentiment score of 1.23 beat Amylyx Pharmaceuticals' score of 0.90 indicating that Aclaris Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aclaris Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amylyx Pharmaceuticals 4 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryAclaris Therapeutics beats Amylyx Pharmaceuticals on 10 of the 17 factors compared between the two stocks. Get Aclaris Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACRS vs. The Competition Export to ExcelMetricAclaris TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$196.08M$2.53B$5.73B$10.28BDividend YieldN/A56.56%5.88%4.63%P/E Ratio-1.3223.2976.7426.53Price / Sales10.47667.50526.07121.12Price / CashN/A169.4937.2060.52Price / Book1.265.2913.946.31Net Income-$132.07M$32.95M$3.29B$271.37M7 Day Performance-11.27%0.85%0.63%2.11%1 Month Performance-3.21%3.80%4.32%6.67%1 Year Performance54.70%-3.99%84.13%27.84% Aclaris Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACRSAclaris Therapeutics3.0391 of 5 stars$1.81-1.6%$8.71+381.5%+54.6%$196.08M$18.72M-1.32100Positive NewsAMLXAmylyx Pharmaceuticals2.3109 of 5 stars$10.44+2.4%$12.25+17.3%+351.3%$909.51M$87.37M-4.18200Analyst ForecastIOVAIovance Biotherapeutics4.3529 of 5 stars$2.38-4.4%$11.90+400.0%-76.6%$901.02M$164.07M-1.93500PHATPhathom Pharmaceuticals2.5337 of 5 stars$12.43+0.7%$17.50+40.8%-41.9%$875.45M$55.25M-2.63110News CoverageURGNUrogen Pharma4.0885 of 5 stars$21.42+13.5%$32.00+49.4%+36.9%$873.47M$90.40M-6.45200Positive NewsHigh Trading VolumeTRVITrevi Therapeutics2.8324 of 5 stars$7.60+8.4%$20.11+164.6%+126.8%$853.66MN/A-18.0920Positive NewsHigh Trading VolumeDNTHDianthus Therapeutics3.1305 of 5 stars$31.80+20.0%$54.00+69.8%+41.8%$852.99M$6.24M-9.7880Gap UpHigh Trading VolumeAVBPArriVent BioPharma2.001 of 5 stars$20.21+0.1%$39.14+93.7%-25.8%$819.09MN/A-5.0340AVXLAnavex Life Sciences3.7758 of 5 stars$9.35-0.5%$44.00+370.6%+57.2%$807.40MN/A-16.4040Positive NewsGap UpABUSArbutus Biopharma1.9286 of 5 stars$4.09-2.6%$5.00+22.2%+3.3%$805.13M$6.17M-14.1090KALVKalVista Pharmaceuticals4.0108 of 5 stars$15.96+0.9%$26.29+64.7%+25.3%$796.38MN/A-4.33100Earnings Report Related Companies and Tools Related Companies Amylyx Pharmaceuticals Competitors Iovance Biotherapeutics Competitors Phathom Pharmaceuticals Competitors Urogen Pharma Competitors Trevi Therapeutics Competitors Dianthus Therapeutics Competitors ArriVent BioPharma Competitors Anavex Life Sciences Competitors Arbutus Biopharma Competitors KalVista Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACRS) was last updated on 9/17/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aclaris Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aclaris Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ACRS Stock Alerts